|
Fri, 03/26/2021 - 09:53 |
DISCOVERY RESEARCH ON AMPA-TYPE GLUTAMATE RECEPTOR ANTAGONIST PERAMPANEL HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2021 |
EISAI |
|
Sun, 11/29/2020 - 23:17 |
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING |
EISAI |
|
Sun, 11/15/2020 - 20:48 |
EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS |
EISAI |
|
Tue, 09/22/2020 - 23:00 |
EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS |
EISAI |
|
Thu, 06/13/2019 - 21:12 |
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 33RD INTERNATIONAL EPILEPSY CONGRESS |
EISAI |
|
Tue, 02/12/2019 - 23:09 |
EISAI SUBMITS APPLICATION IN EUROPE SEEKING APPROVAL FOR FYCOMPA AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY |
EISAI |
|
Wed, 01/30/2019 - 03:32 |
SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES, AS WELL AS NEW FORMULATION |
EISAI |
|
Mon, 11/26/2018 - 20:32 |
Pfizer Receives Six Months Pediatric Exclusivity for LYRICA (pregabalin) |
Pfizer |
|
Mon, 07/30/2018 - 05:55 |
Transaction to result in Nasdaq-listed company focused on developing novel products to treat central nervous system diseases |
Apricus Biosciences |
|
Wed, 06/13/2018 - 12:24 |
Medtronic Launches New Clinician Programmer for Deep Brain Stimulation Therapy |
Medtronic |
|
Thu, 05/17/2018 - 09:00 |
LYRICA (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint |
Pfizer |
|
Tue, 05/01/2018 - 07:34 |
Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy |
Medtronic |
|
Wed, 04/25/2018 - 07:52 |
NIH statement on World Malaria Day 2018 |
NIH |
|
Fri, 12/22/2017 - 08:44 |
Major Study Indicates That Therapy Dogs Provide Significant Benefits to Families of Children Undergoing Treatment for Cancer |
American Humane... |
|
Thu, 08/31/2017 - 22:44 |
Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg |
Daiichi Sankyo |
|
Fri, 08/25/2017 - 03:30 |
Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients |
Daiichi Sankyo |
|
Wed, 08/09/2017 - 10:14 |
More Than 80% of Military Health Facilities Now Offer Complementary and Alternative Medicine Treatments |
RAND Europe |
|
Mon, 06/12/2017 - 11:03 |
Teva Announces Launch of Generic Zetia in the United States |
Teva Pharmaceutical |
|
Mon, 05/22/2017 - 03:28 |
GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to blood eosinophil level |
GlaxoSmithKline |
|
Mon, 03/06/2017 - 10:42 |
GSKs MUSCA study shows Nucala (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype |
GlaxoSmithKline |
|
Thu, 12/01/2016 - 06:14 |
LYRICA (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint |
Pfizer |
|
Wed, 07/06/2016 - 22:35 |
Mylan Launches Generic Fenoglide Tablets |
Viatris |
|
Mon, 07/04/2016 - 22:37 |
Antiepileptic Drug Vimpat Tablets 50 mg and 100 mg have been launched. |
Daiichi Sankyo |
|
Mon, 07/04/2016 - 02:46 |
UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy |
Daiichi Sankyo |
|
Wed, 06/01/2016 - 20:44 |
Mylan Launches First Generic of Doxycycline Hyclate Delayed-Release Tablets, 50 mg |
Viatris |
